Table 2.
Treatment Characteristics | Middle-old (75–84 yrs) (N=2210) N(%) |
Oldest-old (≥85 yrs) (N=831) N(%) |
p value |
---|---|---|---|
Medical therapies on admission | |||
Aspirin | 1641 (74.3%) | 591 (71.1%) | 0.08 |
Theinopyridines | 1376 (62.3%) | 513 (61.7%) | 0.79 |
Anticoagulant use (intravenous or subcutaneous) | 1836 (83.1%) | 667 (80.3%) | 0.07 |
Statin | 1288 (58.3%) | 423 (50.9%) | <0.001 |
Beta-blockers | 1160 (52.5%) | 420 (50.5%) | 0.37 |
Angiotensinogen-converting enzyme inhibitors/angiotensin-receptor blockers | 1108 (50.1%) | 365 (43.9%) | <0.01 |
Interventions | |||
Coronary angiography | 1963 (88.8%) | 607 (73.0%) | <0.0001 |
PCI | 1293 (58.5%) | 445 (53.5%) | 0.01 |
CABG | 315 (14.3%) | 47 (5.7%) | <0.001 |
Revascularization (PCI or CABG) | 1587 (71.8%) | 483 (58.1%) | <0.001 |
In-hospital outcomes | |||
Major bleeding event | 222 (10.0%) | 52 (6.3%) | 0.001 |
Heart Failure | 280 (12.7%) | 148 (17.8%) | <0.001) |
Cardiogenic shock | 92 (4.2%) | 23 (2.8%) | 0.07 |
Arrhythmia | 397 (18.0%) | 155 (18.7%) | 0.66 |
Acute kidney injury | 527 (23.8%) | 190 (22.9%) | 0.56 |
In-hospital mortality | 22 (1.0%) | 13 (1.6%) | 0.19 |
PCI- percutaneous coronary intervention, CABG- coronary artery bypass grafting